193 related articles for article (PubMed ID: 24974778)
21. Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review.
van Baardwijk A; Tomé WA; van Elmpt W; Bentzen SM; Reymen B; Wanders R; Houben R; Ollers M; Lambin P; De Ruysscher D
Radiother Oncol; 2012 Nov; 105(2):145-9. PubMed ID: 23068707
[TBL] [Abstract][Full Text] [Related]
22. Reirradiation with stereotactic body radiotherapy for primary or secondary lung malignancies: Tumor control probability and safety analyses.
Wang HH; Chen Y; Liu X; Zaorsky NG; Mani K; Niu ZM; Zheng BY; Zeng HY; Yan YY; Li YJ; He Y; Ji CZ; Sun BS; Meng MB
Radiother Oncol; 2023 Oct; 187():109817. PubMed ID: 37480993
[TBL] [Abstract][Full Text] [Related]
23. Relative clinical effectiveness of carbon ion radiotherapy: theoretical modelling for H&N tumours.
Antonovic L; Dasu A; Furusawa Y; Toma-Dasu I
J Radiat Res; 2015 Jul; 56(4):639-45. PubMed ID: 25858182
[TBL] [Abstract][Full Text] [Related]
24. Severe hypofractionation: non-homogeneous tumour dose delivery can counteract tumour hypoxia.
Ruggieri R; Naccarato S; Nahum AE
Acta Oncol; 2010 Nov; 49(8):1304-14. PubMed ID: 20500031
[TBL] [Abstract][Full Text] [Related]
25. Altered fractionation outcomes for hypoxic head and neck cancer using the HYP-RT Monte Carlo model.
Harriss-Phillips WM; Bezak E; Yeoh EK
Br J Radiol; 2013 Apr; 86(1024):20120443. PubMed ID: 23392195
[TBL] [Abstract][Full Text] [Related]
26. Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study.
Søvik A; Malinen E; Bruland ØS; Bentzen SM; Olsen DR
Phys Med Biol; 2007 Jan; 52(2):499-513. PubMed ID: 17202629
[TBL] [Abstract][Full Text] [Related]
27. A simple mathematical model of cyclic hypoxia and its impact on hypofractionated radiotherapy.
Taylor E
Med Phys; 2023 Mar; 50(3):1893-1904. PubMed ID: 36594511
[TBL] [Abstract][Full Text] [Related]
28. Estimation of the α/β ratio of non-small cell lung cancer treated with stereotactic body radiotherapy.
Klement RJ; Sonke JJ; Allgäuer M; Andratschke N; Appold S; Belderbos J; Belka C; Dieckmann K; Eich HT; Flentje M; Grills I; Eble M; Hope A; Grosu AL; Semrau S; Sweeney RA; Hörner-Rieber J; Werner-Wasik M; Engenhart-Cabillic R; Ye H; Guckenberger M
Radiother Oncol; 2020 Jan; 142():210-216. PubMed ID: 31431371
[TBL] [Abstract][Full Text] [Related]
29. Monte Carlo radiotherapy simulations of accelerated repopulation and reoxygenation for hypoxic head and neck cancer.
Harriss-Phillips WM; Bezak E; Yeoh EK
Br J Radiol; 2011 Oct; 84(1006):903-18. PubMed ID: 21933980
[TBL] [Abstract][Full Text] [Related]
30. Translational and rotational intra- and inter-fractional errors in patient and target position during a short course of frameless stereotactic body radiotherapy.
Josipovic M; Persson GF; Logadottir A; Smulders B; Westmann G; Bangsgaard JP
Acta Oncol; 2012 May; 51(5):610-7. PubMed ID: 22263924
[TBL] [Abstract][Full Text] [Related]
31. A radiobiological model of reoxygenation and fractionation effects.
Guerrero M; Carlson DJ
Med Phys; 2017 May; 44(5):2002-2010. PubMed ID: 28273349
[TBL] [Abstract][Full Text] [Related]
32. The impact of hypofractionation on simultaneous dose-boosting to hypoxic tumor subvolumes.
Ruggieri R; Nahum AE
Med Phys; 2006 Nov; 33(11):4044-55. PubMed ID: 17153384
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients.
Taremi M; Hope A; Dahele M; Pearson S; Fung S; Purdie T; Brade A; Cho J; Sun A; Bissonnette JP; Bezjak A
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):967-73. PubMed ID: 21377293
[TBL] [Abstract][Full Text] [Related]
34. Tumor Control and Toxicity for Common Stereotactic Body Radiation Therapy Dose-Fractionation Regimens in Stage I Non-Small Cell Lung Cancer.
Stephans KL; Woody NM; Reddy CA; Varley M; Magnelli A; Zhuang T; Qi P; Videtic GMM
Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):462-469. PubMed ID: 29353658
[TBL] [Abstract][Full Text] [Related]
35. Lung density changes after stereotactic radiotherapy: a quantitative analysis in 50 patients.
Palma DA; van Sörnsen de Koste J; Verbakel WF; Vincent A; Senan S
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):974-8. PubMed ID: 20932655
[TBL] [Abstract][Full Text] [Related]
36. Toxicity and Efficacy of Stereotactic Ablative Body Radiotherapy for Moderately Central Non-small Cell Lung Cancers Using 50 Gy in Five Fractions.
Rulach R; McLoone P; Lumsden G; McKay S; MacLaren V; Macphee J; Moore K; Omand M; Sproule M; Currie S; Aitken A; Ferguson R; Valentine R; Houston P; Harrow S; Hicks J
Clin Oncol (R Coll Radiol); 2020 Apr; 32(4):250-258. PubMed ID: 31607611
[TBL] [Abstract][Full Text] [Related]
37. Altered fractionation schemes in radiotherapy.
Stuschke M; Pöttgen C
Front Radiat Ther Oncol; 2010; 42():150-156. PubMed ID: 19955801
[TBL] [Abstract][Full Text] [Related]
38. Radiobiologically derived biphasic fractionation schemes to overcome the effects of tumour hypoxia.
Joseph N; Kirkby NF; Hoskin PJ; West CML; Choudhury A; Dale RG
Br J Radiol; 2020 Aug; 93(1112):20190250. PubMed ID: 32462907
[TBL] [Abstract][Full Text] [Related]
39. Changes in position and volume of lung cancer target volumes during stereotactic body radiotherapy (SBRT): is image guidance necessary?
Yi BS; Perks J; Houston R; Stern R; Purdy JA; Chen AM
Technol Cancer Res Treat; 2011 Oct; 10(5):495-504. PubMed ID: 21895034
[TBL] [Abstract][Full Text] [Related]
40. Low-dose hilar and mediastinal stereotactic body radiation therapy for non-small cell lung cancer: Analysis of outcomes in patients receiving one or multiple courses of treatment.
Kowalchuk RO; Waters MR; Richardson M; Spencer K; Larner JM; Kersh CR
Thorac Cancer; 2020 Jul; 11(7):2005-2013. PubMed ID: 32469465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
